VWF/FVIII concentrates
| Characteristic . | Alphanate . | Humate-P . | Wilate . | Vonvendi . |
|---|---|---|---|---|
| VWF RCo:FVIII ratio | >0.4:1.0, varies by lot | 2.4:1.0 | 1.0:1.0 | 1.3:1.0* |
| Mean VWF RCo t 1/2, hours, ± SD | 7.67 ± 3.32 | 12.2 ± 5.2 | 19.6 ± 6.9 | 19.3 ± 10.99 |
| Derivation | Plasma-derived | Plasma-derived | Plasma-derived | Recombinant |
| Indications | Hemophilia A and VWD type I/II | All VWD subtypes, adult and pediatric | All VWD subtypes, adult and pediatric | All VWD subtypes, adults >18 years |
| Clinical notes | Not indicated in severe type 3 VWD because of increased risk for alloantibody formation1 | Contains HMW VWF multimers | Contains ultralarge and HMW multimers; does not increase FVIII:C in type 3 VWD. Separate FVIII replacement may be necessary |
| Characteristic . | Alphanate . | Humate-P . | Wilate . | Vonvendi . |
|---|---|---|---|---|
| VWF RCo:FVIII ratio | >0.4:1.0, varies by lot | 2.4:1.0 | 1.0:1.0 | 1.3:1.0* |
| Mean VWF RCo t 1/2, hours, ± SD | 7.67 ± 3.32 | 12.2 ± 5.2 | 19.6 ± 6.9 | 19.3 ± 10.99 |
| Derivation | Plasma-derived | Plasma-derived | Plasma-derived | Recombinant |
| Indications | Hemophilia A and VWD type I/II | All VWD subtypes, adult and pediatric | All VWD subtypes, adult and pediatric | All VWD subtypes, adults >18 years |
| Clinical notes | Not indicated in severe type 3 VWD because of increased risk for alloantibody formation1 | Contains HMW VWF multimers | Contains ultralarge and HMW multimers; does not increase FVIII:C in type 3 VWD. Separate FVIII replacement may be necessary |
HMW, high molecular weight; SD, standard deviation; t 1/2, half-life.
Although it contains no FVIII, it can increase endogenous FVIII:C level above 40% within 6 hours in majority of patients.11